Cardinal Health, Inc. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter and nine months ended March 31, 1997. Cardinal Health, Inc. is a diversified healthcare services company. The financial statements have been restated to reflect the pooling-of-interests mergers with Medicine Shoppe International, Pyxis Corporation, and Owen Healthcare, Inc. (completed March 18, 1997). A merger with PCI Services, Inc. was completed in October 1996.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 | 9 Months 1997 | 9 Months 1996 |
|---|---|---|---|---|
| Net Revenues ($000s) | $2,825,500 | $2,352,254 | $8,177,382 | $6,824,765 |
| Gross Margin ($000s) | $243,658 | $203,587 | $664,344 | $569,480 |
| Gross Margin % | 8.62% | 8.65% | 8.12% | 8.34% |
| Operating Earnings ($000s) | $74,352 | $81,205 | $226,210 | $195,324 |
| Net Earnings ($000s) | $36,228 | $44,691 | $119,229 | $106,620 |
| Diluted EPS ($) | $0.33 | $0.43 | $1.10 | $1.04 |
| Cash & Equivalents ($000s) | $12,521 | $304,281 (Jun '96) | $12,521 | $154,229 (Mar '96) |
| Working Capital ($000s) | $1,044,796 | $924,414 (Jun '96) | $1,044,796 | N/A |
Debt & Liquidity: Total current liabilities were $1.42 billion. The company holds a shelf registration for up to $400 million in long-term debt. Cash flow from operations was negative $332.3 million for the nine months ended March 31, 1997, primarily due to significant increases in inventory and receivables.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 20% year-over-year for both the quarter and nine-month periods, driven by pharmaceutical distribution growth, new customer additions, and the PCI merger.
- Merger Costs: Reported operating earnings were reduced by $39.6 million in merger-related costs for the quarter and $57.0 million for the nine months. These costs relate primarily to the Owen and PCI mergers.
- Pro Forma Performance: Excluding non-recurring merger costs, pro forma net earnings for the quarter were $63.8 million ($0.58 EPS) and for the nine months were $159.4 million ($1.47 EPS).
- Margin Compression: Gross margin percentage declined slightly (8.12% vs 8.34% for nine months) due to a shift in revenue mix toward lower-margin pharmaceutical distribution activities.
- Liquidity Shift: Cash and equivalents dropped from $304.3 million to $12.5 million, and marketable securities were depleted, as capital was deployed into inventory ($283.3 million increase) and receivables ($133.5 million increase).
Guidance, Outlook, and Risks
- Outlook: Management attributes growth to internal expansion, the Kmart partnership, and opportunities arising from a competitor's financial deterioration. No specific forward-looking financial guidance was provided in this text.
- Legal Proceedings: The company is a defendant in consolidated antitrust litigation ("Brand Name Prescription Drug Litigation") alleging price-fixing. Summary judgment was granted in the company's favor in April 1996, but plaintiffs have appealed. Management believes the allegations are without merit and does not expect a material adverse effect.
- Accounting Changes: The company will adopt SFAS 128 (Earnings per Share) in the fiscal quarter ending December 31, 1997, though the impact is not expected to be significant.
Investor Verification Checklist
- Verify the sustainability of revenue growth given the shift to lower-margin pharmaceutical distribution.
- Monitor the resolution of the antitrust litigation and potential appeal outcomes.
- Assess the company's ability to manage working capital requirements, given the significant cash outflow for inventory and receivables.
- Review the integration progress of the Owen Healthcare and PCI Services mergers to ensure projected synergies are realized.
- Confirm the accuracy of pro forma earnings adjustments regarding merger costs.